You should also make your doctor aware of any side effects you might experience while using Tremfya. Both plaque psoriasis ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.

At 48 weeks, endoscopic response was achieved in 44.3% and 51.3% of patients in the Tremfya 100 mg SC every eight weeks group ...

A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.